References
- National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents. Proposed standard M26-P. National Committee for Clinical Laboratory Standards, Villanova, Pa. 1987.
- National Committee for Clinical Laboratory Standards. Methods for dilution of antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A. National Committee for Clinical Laboratory Standards, Villanova, Pa. 1985.
- Zak O, Vischer WA, Schenk C, et al. CGP 9000: a new orally active, broad spectrum cephalosporin. J Antibiot 1976: 29: 653–655.
- Greenwood D. In vitro activity against E. coli of CGP 9000, a new oral cephalosporin. J Antibiot 1978; 31: 697–702.
- Vischer WA, Zak O, Konopka EA, Fehlmann H, Regos J, Tosch W. Experimental evaluation of CGP 9000, a new oral active cephalosporin. In: W. Siegenthaler and R. Luthy (ed.) Current Chemotherapy Vol. 2, Washington, D.C. American Society for Microbiology, 1978: 825–827.
- Mashimo K, Kunii O, Ishigami J, Matsumoto K. Clinical experience with CGP 9000 in Japan. In: J.D. Nelson and C. Grassi (ed.) Current Chemotherapy and Infectious Disease, Vol. 1. Washington, D.C: American Society for Microbiology 1980: 206–207.
- Bergan T. Pharmacokinetics of a new cephalosporin CGP 9000 (cefroxadine) in healthy volunteers. Chemotherapy, 1980; 26: 225–230.
- Gillett AP, Wise R. Penetration of four cephalosporin: into tissue fluid in man. Lancet 1978; ii: 962–964.